Accelerating the clinical development of treatments for dengue: WHO dengue therapeutics landscape analysis and target product profiles
Year: 2026
Type: review
Abstract: Dengue, an Aedes mosquito-borne viral infection, is on the rise with climate and demographic change. In 2023, WHO declared dengue its highest grade of emergency, following the largest number of cases and deaths in recorded history. This emergency highlighted the absence of safe and effective dengue-specific treatments as a gap in the product landscape for care for people with dengue. To accelerate development of dengue-specific treatments for wide implementation and access in all dengue-endemic countries, WHO conducted a landscape analysis of the dengue therapeutics pipeline and convened a global expert and public consultation to develop target product profiles for treatments for non-severe and severe dengue. These target product profiles provide strategic guidance for product developers, regulators, procurement agencies, and funders on the intended use, target populations, and key product characteristics of dengue-specific treatments required to meet public health needs, setting clear targets to drive development of dengue drugs accessible to those who need them the most.
Source: The Lancet Microbe
Authors: Xin Hui S Chan, Anna P Durbin, Gathsaurie Neelika Malavige, Fausto Baldanti, Marco Cavaleri, Fazle Rabbi Chowdhury, Isadora C de Siqueira, Madiha Hashmi, Trung Trieu Huynh, Jenny G Low, Tariq A Madani, Johan Neyts, Usa Thisyakorn, Sandra L Valderrama-Beltrán, Janet V Diaz, Vasee Moorthy, Martina Penazzato, Diana P Rojas, Raman Velayudhan
Institutions: World Health Organization, UK Health Security Agency, Johns Hopkins University, University of Sri Jayewardenepura, University of Pavia, Policlinico San Matteo Fondazione, European Medicines Agency, Bangladesh Medical University, Fundação Oswaldo Cruz, Ziauddin University, Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Singapore General Hospital, SingHealth Duke-NUS Academic Medical Centre, Duke-NUS Medical School, King Abdulaziz University, Rega Institute for Medical Research, KU Leuven, Chulalongkorn University, Pontificia Universidad Javeriana
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $7,280
OpenAlex ID: W7206198406